S&P 500
5.554,13 +58,61 (+1,07%) Nasdaq
17.395,53 +369,65 (+2,17%) NIKKEI 225
35.619,77 -539,39 (-1,49%) Dólar/Euro
1,1019 -0,0004 (-0,03%) Petróleo Brent
70,52 +1,33 (+1,92%) Bitcoin EUR
52.289,16 -209,90 (-0,40%)
Alnylam Pharmaceuticals, Inc. (ALNY)
Después del cierre:
Alnylam Pharmaceuticals, Inc.
675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142
United States
617 551 8200
https://www.alnylam.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 2100
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Yvonne L. Greenstreet M.B.A., MBChB | CEO & Director | 2,15M | N/A | 1963 |
| Mr. Jeffrey V. Poulton M.B.A. | CFO & Executive VP | 1,05M | N/A | 1968 |
| Dr. Akshay K. Vaishnaw M.D., Ph.D. | Chief Innovation Officer & Member of the Scientific Advisory Board | 1,12M | 5,9M | 1963 |
| Dr. Pushkal P. Garg M.D. | Chief Medical Officer | 1,06M | 517,75k | 1968 |
| Mr. Tolga Tanguler M.B.A. | Executive VP & Chief Commercial Officer | 971,3k | N/A | 1973 |
| Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer | N/A | N/A | N/A |
| Dr. Kevin Joseph Fitzgerald Ph.D. | Senior VP, Head of Research & Chief Scientific Officer | N/A | N/A | 1969 |
| Ms. Christine Regan Lindenboom | Senior VP of Investor Relations & Corporate Communications | N/A | N/A | 1981 |
| Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer | N/A | N/A | N/A |
| Mr. Evan Lippman M.B.A. | Chief Corporate Development & Strategy Officer | N/A | N/A | N/A |
Descripción
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de Alnylam Pharmaceuticals, Inc., a día 1 de septiembre de 2024, es 4. Las puntuaciones base son Auditoría: 7; Tablero: 2; Derechos de los accionistas: 6; Compensación: 5.
